Eva Kubala Havrdova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6961707/publications.pdf Version: 2024-02-01

296 papers	31,152 citations	10389 72 h-index	4645 170 g-index
319	319	319	18686
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Quantitative proteomic analysis of cerebrospinal fluid of women newly diagnosed with multiple sclerosis. International Journal of Neuroscience, 2022, 132, 724-734.	1.6	6
2	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. European Journal of Neurology, 2022, 29, 1082-1090.	3.3	11
3	The clinical and paraclinical correlates of employment status in multiple sclerosis. Neurological Sciences, 2022, 43, 1911-1920.	1.9	4
4	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology, 2022, 269, 1670-1677.	3.6	39
5	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Multiple Sclerosis and Related Disorders, 2022, 57, 103389.	2.0	6
6	Pregnancyâ€induced brain magnetic resonance imaging changes in women with multiple sclerosis. European Journal of Neurology, 2022, 29, 1446-1456.	3.3	7
7	Steroid Sulfation in Neurodegenerative Diseases. Frontiers in Molecular Biosciences, 2022, 9, 839887.	3.5	13
8	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	2.2	8
9	Time course of lesion-induced atrophy in multiple sclerosis. Journal of Neurology, 2022, 269, 4478-4487.	3.6	3
10	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
11	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal, 2022, 28, 842-846.	3.0	13
12	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.1	12
13	Periventricular gradient of T1 tissue alterations in multiple sclerosis. NeuroImage: Clinical, 2022, 34, 103009.	2.7	9
14	Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease. Journal of Clinical Medicine, 2022, 11, 2832.	2.4	2
15	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	3.3	1
16	Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 220-231.	3.0	55
17	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. Multiple Sclerosis Journal, 2021, 27, 479-482.	3.0	7
18	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11

#	Article	IF	CITATIONS
19	Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 52-60.	3.0	41
20	Interpretation of Brain Volume Increase in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 401-407.	2.0	6
21	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098213.	3.5	30
22	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
23	Isolated Cognitive Decline in Neurologically Stable Patients with Multiple Sclerosis. Diagnostics, 2021, 11, 464.	2.6	9
24	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	15
25	Effects of Menopause in Women With Multiple Sclerosis: An Evidence-Based Review. Frontiers in Neurology, 2021, 12, 554375.	2.4	18
26	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology, 2021, 96, .	1.1	41
27	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study. JAMA Neurology, 2021, 78, 558.	9.0	132
28	The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 2021, 144, 2954-2963.	7.6	98
29	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Multiple Sclerosis and Related Disorders, 2021, 51, 102844.	2.0	19
30	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.1	15
31	The effectiveness of natalizumab vs fingolimod–A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012.	2.0	8
32	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. Journal of Neuroimmunology, 2021, 357, 577627.	2.3	33
33	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Computer Methods and Programs in Biomedicine, 2021, 208, 106180.	4.7	21
34	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
35	Severely disabled multiple sclerosis patients can achieve the performance of healthy subjects after expiratory muscle strength training. Multiple Sclerosis and Related Disorders, 2021, 55, 103187.	2.0	4
36	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54

Eva Kubala Havrdova

#	Article	IF	CITATIONS
37	Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis Journal, 2021, 27, 2001-2013.	3.0	9
38	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis. Diagnostics, 2021, 11, 2230.	2.6	2
39	Oral cladribine in the treatment of multiple sclerosis – data from the national registry ReMuS® registry. Ceska A Slovenska Neurologie A Neurochirurgie, 2021, 84/117, .	0.1	1
40	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
41	Clinical and therapeutic predictors of disease outcomes in AQP4-IgC+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
42	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
43	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	2.0	14
44	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. JAMA Neurology, 2020, 77, 1496.	9.0	21
45	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	1.5	8
46	Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ. Frontiers in Immunology, 2020, 11, 1527.	4.8	24
47	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	9.0	21
48	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24
49	Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642097522.	3.5	5
50	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
51	Quality of Life Improves with Alemtuzumab Over 6ÂYears in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2020, 9, 443-457.	3.2	4
52	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
53	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
54	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	10.2	219

#	Article	IF	CITATIONS
55	Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	24
56	Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. Journal of Neurology, 2020, 267, 2851-2864.	3.6	8
57	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
58	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Multiple Sclerosis Journal, 2019, 25, 1255-1262.	3.0	37
59	Additive Effect of Spinal Cord Volume, Diffuse and Focal Cord Pathology on Disability in Multiple Sclerosis. Frontiers in Neurology, 2019, 10, 820.	2.4	16
60	PND68 COST-EFFECTIVENESS OF OCRELIZUMAB COMPARED TO FINGOLIMOD OR DMF IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CZECH REPUBLIC. Value in Health, 2019, 22, S282.	0.3	0
61	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1009-1020.	10.2	191
62	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurology, The, 2019, 18, 1021-1033.	10.2	184
63	Slowed articulation rate is associated with information processing speed decline in multiple sclerosis: A pilot study. Journal of Clinical Neuroscience, 2019, 65, 28-33.	1.5	16
64	Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?. Journal of Neural Transmission, 2019, 126, 731-737.	2.8	3
65	Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1273-1288.	3.0	29
66	A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. American Journal of Neuroradiology, 2019, 40, 446-452.	2.4	15
67	Real-Life Outcome in Multiple Sclerosis in the Czech Republic. Multiple Sclerosis International, 2019, 2019, 1-8.	0.8	6
68	Biofeedback Based Home Balance Training can Improve Balance but Not Gait in People with Multiple Sclerosis. Multiple Sclerosis International, 2019, 2019, 1-9.	0.8	8
69	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	2.3	22
70	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
71	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35
72	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336

#	Article	IF	CITATIONS
73	Antiâ€inflammatory diseaseâ€modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology, 2019, 26, 363-370.	3.3	12
74	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Multiple Sclerosis Journal, 2019, 25, 1605-1617.	3.0	57
75	Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 541-553.	3.0	32
76	"The spectrum of MRI findings of progressive multifocal leukoencephalopathy in patients with multiple sclerosis in the Czech Republic". Ceska A Slovenska Neurologie A Neurochirurgie, 2019, 82/115, 381-390.	0.1	1
77	Neurorehabilitation of gait impairment usÂÂing functional electrical stimulation –  curÂrent findings from randomized clinical trials. Ceska A Slovenska Neurologie A Neurochirurgie, 2019, 82/115, 621-626.	0.1	0
78	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients. Journal of the Neurological Sciences, 2018, 388, 87-93.	0.6	7
79	Establishing pathological cut-offs for lateral ventricular volume expansion rates. NeuroImage: Clinical, 2018, 18, 494-501.	2.7	26
80	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod―[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
81	Management of multiple sclerosis patients in central European countries: current needs and potential solutions. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875918.	3.5	17
82	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
83	The Role of Highâ€Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 328-337.	2.0	4
84	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	7.6	115
85	Cognitive clinicoâ€radiological paradox in early stages of multiple sclerosis. Annals of Clinical and Translational Neurology, 2018, 5, 81-91.	3.7	26
86	<scp>ECTRIMS</scp> / <scp>EAN</scp> guideline on the pharmacological treatment of people with multiple sclerosis. European Journal of Neurology, 2018, 25, 215-237.	3.3	147
87	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
88	Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management. European Journal of Neurology, 2018, 25, 739-746.	3.3	12
89	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731876064.	1.0	32
90	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurology, The, 2018, 17, 405-415.	10.2	238

#	Article	IF	CITATIONS
91	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
92	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.0	2
93	Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1617-1626.	3.0	36
94	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2018, 19, 153-160.	2.0	101
95	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. NeuroImage: Clinical, 2018, 17, 444-451.	2.7	58
96	PND18 - PROGRESSION OF DISABILITY IN PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: A RETROSPECTIVE COHORT STUDY USING DATA FROM THE MSBASE REGISTRY AND A CONTEXTUALISATION WITH AN EXISTING NATURAL HISTORY DATASET. Value in Health, 2018, 21, S332.	0.3	0
97	060â€Association of brain volume loss and neda outcomes in patients with relapsing multiple sclerosis in the opera i and opera ii studies (ENCORE). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A25.1-A25.	1.9	0
98	Do eyes with and without optic neuritis in multiple sclerosis age equally?. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2281-2285.	2.2	5
99	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. Annals of Neurology, 2018, 84, 958-959.	5.3	10
100	044â€Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A18.2-A19.	1.9	0
101	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
102	Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, .	5.0	46
103	ls no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Multiple Sclerosis Journal, 2017, 23, 242-252.	3.0	39
104	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis Journal, 2017, 23, 94-105.	3.0	95
105	Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 51-61.	3.0	39
106	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	3.0	126
107	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
108	Survey of diagnostic and treatment practices for multiple sclerosis in Europe. European Journal of Neurology, 2017, 24, 516-522.	3.3	34

#	Article	IF	CITATIONS
109	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurology, 2017, 74, 459.	9.0	199
110	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
111	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
112	Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmunity Reviews, 2017, 16, 658-665.	5.8	106
113	A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Longâ€Term Comparative Study. Journal of Neuroimaging, 2017, 27, 620-629.	2.0	20
114	Effect of delayedâ€release dimethyl fumarate on no evidence of disease activity in relapsing–remitting multiple sclerosis: integrated analysis of the phase <scp>III DEFINE</scp> and <scp>CONFIRM</scp> studies. European Journal of Neurology, 2017, 24, 726-733.	3.3	50
115	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Multiple Sclerosis Journal, 2017, 23, 1736-1747.	3.0	18
116	"No evident disease activityâ€i The use of combined assessments in the management of patients with multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1179-1187.	3.0	126
117	MxA <scp>mRNA</scp> decrease preceding <scp>NA</scp> b detection in <scp>IFN</scp> βâ€ŧreated <scp>MS</scp> patients. Brain and Behavior, 2017, 7, e00644.	2.2	1
118	Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 11, 18-24.	2.0	12
119	Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients. Journal of Lipid Research, 2017, 58, 403-411.	4.2	43
120	Alemtuzumab CARE-MS I 5-year follow-up. Neurology, 2017, 89, 1107-1116.	1.1	188
121	Alemtuzumab CARE-MS II 5-year follow-up. Neurology, 2017, 89, 1117-1126.	1.1	232
122	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
123	timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, e1.11-e1.	1.9	Ο
124	New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic. Multiple Sclerosis Journal, 2017, 23, 41-52.	3.0	13
125	Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. NeuroImage: Clinical, 2017, 15, 769-779.	2.7	48
126	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.0	9

#	Article	IF	CITATIONS
127	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1367-1376.	3.0	26
128	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
129	Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach. European Journal of Neurology, 2017, 24, 292-301.	3.3	38
130	PO114â€Neda achievement by time interval with daclizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A42.1-A42.	1.9	0
131	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94
132	PO129â€Neda analysis by epoch in the opera studies of ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A46.2-A46.	1.9	3
133	Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients. BMC Neurology, 2017, 17, 145.	1.8	10
134	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1423-1437.	2.0	25
135	Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβ. PLoS ONE, 2017, 12, e0169957.	2.5	1
136	Fingolimod in Real Clinical Practice. Ceska A Slovenska Neurologie A Neurochirurgie, 2017, 80/113, 213-219.	0.1	0
137	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
138	Daclizumab highâ€yield process reduced the evolution of new gadoliniumâ€enhancing lesions to T1 black holes in patients with relapsingâ°'remitting multiple sclerosis. European Journal of Neurology, 2016, 23, 412-415.	3.3	9
139	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
140	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	3.3	21
141	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
142	Comparative efficacy of first-line natalizumab vs IFN-Î ² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
143	Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Multiple Sclerosis and Related Disorders, 2016, 6, 66-72.	2.0	18
144	Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. Journal of Neurology, 2016, 263, 1287-1295.	3.6	158

#	Article	IF	CITATIONS
145	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.1	55
146	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS. Neurology, 2016, 87, 1464-1472.	1.1	28
147	Reliable measurements of brain atrophy in individual patients with multiple sclerosis. Brain and Behavior, 2016, 6, e00518.	2.2	58
148	Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurology and Therapy, 2016, 5, 169-182.	3.2	16
149	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology, 2016, 16, 117.	1.8	40
150	Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded) Tj ETQq0 0 () rgBT /Ove 1.4	erlogk 10 Tf 5
151	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.30-e1.	1.9	0
152	DACLIZUMAB HYP IN MULTIPLE SCLEROSIS: 3-YEAR RESULTS FROM SELECTED. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.48-e1.	1.9	0
153	DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.47-e1.	1.9	1
154	Predictors of longâ€ŧerm disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
155	MENACTRIMS congress 2016. Multiple Sclerosis Journal, 2016, 22, NP1-NP24.	3.0	3
156	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	10.2	266
157	A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Multiple Sclerosis Journal, 2016, 22, 1709-1718.	3.0	69
158	Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Multiple Sclerosis Journal, 2016, 22, 770-781.	3.0	37
159	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis Journal, 2016, 22, 520-532.	3.0	34
160	â€~Hidden' factors influencing quality of life in patients with multiple sclerosis. European Journal of Neurology, 2015, 22, 28-33.	3.3	48
161	ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.9-e4.	1.9	0
162	Daclizumab HYP reduces total disability burden of patients with multiple sclerosis: results from an exploratory area under the curve analysis. Journal of the Neurological Sciences, 2015, 357, e300-e301.	0.6	0

#	Article	IF	CITATIONS
163	Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium. Clinical and Experimental Immunology, 2015, 181, 385-400.	2.6	72
164	Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurology and Therapy, 2015, 4, 93-104.	3.2	80
165	MANAGEMENT OF ADVERSE REACTIONS TO ALEMTUZUMAB INFUSION. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.23-e4.	1.9	1
166	Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
167	Natalizumab improves ambulation in relapsingâ~'remitting multiple sclerosis: results from the prospective <scp>TIMER</scp> study and a retrospective analysis of <scp>AFFIRM</scp> . European Journal of Neurology, 2015, 22, 570-577.	3.3	16
168	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
169	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology, 2015, 84, 1145-1152.	1.1	63
170	Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Therapeutic Advances in Neurological Disorders, 2015, 8, 31-45.	3.5	134
171	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. Multiple Sclerosis and Related Disorders, 2015, 4, 202-218.	2.0	85
172	Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5). Journal of NeuroEngineering and Rehabilitation, 2015, 12, 14.	4.6	53
173	Early magnetic resonance imaging predictors of clinical progression after 48Âmonths in clinically isolated syndrome patients treated with intramuscular interferon βâ€Ia. European Journal of Neurology, 2015, 22, 1113-1123.	3.3	25
174	<scp>BREMSO</scp> : a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	3.3	32
175	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
176	Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. Journal of Lipid Research, 2015, 56, 2010-2018.	4.2	45
177	Impaired ambulation and steroid therapy impact negatively on bone health in multiple sclerosis. European Journal of Neurology, 2015, 22, 624-632.	3.3	17
178	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
179	Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. American Journal of Neuroradiology, 2015, 36, 1457-1464.	2.4	13
180	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162

#	Article	IF	CITATIONS
181	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis–related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clinical Therapeutics, 2015, 37, 2543-2551.	2.5	9
182	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
183	Increased Serum Levels of C21 Steroids in Female Patients With Multiple Sclerosis. Physiological Research, 2015, 64, S247-S254.	0.9	7
184	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. International Journal of MS Care, 2015, 17, 236-243.	1.0	47
185	Neuromyelitis Optica Spectrum Disorders –  Retrospective Analysis of Clinical and Paraclinical Findings. Ceska A Slovenska Neurologie A Neurochirurgie, 2015, 78/111, 72-77.	0.1	2
186	The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus. Neuroendocrinology Letters, 2015, 36, 564-71.	0.2	14
187	Disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Multiple Sclerosis Journal, 2014, 20, 464-470.	3.0	25
188	MRI correlates of disability progression in patients with CIS over 48Âmonths. NeuroImage: Clinical, 2014, 6, 312-319.	2.7	39
189	Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment. Journal of the Neurological Sciences, 2014, 347, 229-234.	0.6	8
190	Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis. Neurology, 2014, 82, 573-581.	1.1	249
191	The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis. JAMA Neurology, 2014, 71, 1386.	9.0	45
192	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Journal of Neuroimmunology, 2014, 273, 58-64.	2.3	21
193	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology, 2014, 261, 773-783.	3.6	168
194	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. Journal of Neurology, 2014, 261, 316-323.	3.6	18
195	Efficacy and safety of BC-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion, 2014, 30, 613-627.	1.9	70
196	Effects of BC-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study. Multiple Sclerosis Journal, 2014, 20, 253-257.	3.0	40
197	Lymphocyte subset dynamics following alemtuzumab treatment in patients who relapsed on a prior therapy. Journal of Neuroimmunology, 2014, 275, 63-64.	2.3	2
198	Should rapid decrease of NK cells be marker of conversion from CIS to CDMS?. Journal of Neuroimmunology, 2014, 275, 88.	2.3	0

#	Article	IF	CITATIONS
199	Complement activation in patients with neuromyelitis optica. Journal of Neuroimmunology, 2014, 274, 185-191.	2.3	54
200	Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 424-433.	2.5	14
201	Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 859-864.	1.9	35
202	Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. Journal of Neurology, 2014, 261, 1735-1744.	3.6	45
203	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology, 2014, 83, 1210-1216.	1.1	30
204	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. Multiple Sclerosis and Related Disorders, 2014, 3, 513-519.	2.0	34
205	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurology, The, 2014, 13, 472-481.	10.2	83
206	Future MS care: a consensus statement of the MS in the 21st Century Steering Group. Journal of Neurology, 2013, 260, 462-469.	3.6	27
207	Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis. JAMA Neurology, 2013, 70, 248.	9.0	13
208	An integrated analysis of relapses requiring intravenous steroid use and multiple sclerosis (MS)-related hospitalizations from the BG-12 (dimethyl fumarate) phase 3 define and confirm studies. Value in Health, 2013, 16, A101-A102.	0.3	2
209	Recommendations for the Use of Prolongedâ€Release Fampridine in Patients with Multiple Sclerosis (<scp>MS</scp>). CNS Neuroscience and Therapeutics, 2013, 19, 302-306.	3.9	11
210	Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM. Expert Opinion on Pharmacotherapy, 2013, 14, 2145-2156.	1.8	34
211	Oral BC-12 in Multiple Sclerosis. New England Journal of Medicine, 2013, 368, 1652-1653.	27.0	3
212	Development of gray matter atrophy in relapsing–remitting multiple sclerosis is not gender dependent: Results of a 5-year follow-up study. Clinical Neurology and Neurosurgery, 2013, 115, S42-S48.	1.4	12
213	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2013, 381, 2167-2175.	13.7	269
214	Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically isolated syndromes. Journal of Neuroimmunology, 2013, 263, 121-127.	2.3	14
215	Gastrointestinal tolerability events in relapsing–/INS;remitting multiple sclerosis patients treated with BG-12 (dimethyl fumarate): Integrated analysis of DEFINE and CONFIRM. Journal of the Neurological Sciences, 2013, 333, e368-e369.	0.6	0
216	Multiple sclerosis susceptibility loci do not alter clinical and MRI outcomes in clinically isolated syndrome. Genes and Immunity, 2013, 14, 244-248.	4.1	18

#	Article	IF	CITATIONS
217	Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis. European Journal of Neurology, 2013, 20, 1032-1042.	3.3	8
218	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study. Journal of Neurology, 2013, 260, 2286-2296.	3.6	68
219	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. Radiology, 2013, 268, 831-841.	7.3	145
220	Evolution of Cortical and Thalamus Atrophy and Disability Progression in Early Relapsing-Remitting MS during 5 Years. American Journal of Neuroradiology, 2013, 34, 1931-1939.	2.4	90
221	Lipid profiles are associated with lesion formation over 24â€months in interferon-β treated patients following the first demyelinating event. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1186-1191.	1.9	114
222	Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Multiple Sclerosis International, 2013, 2013, 1-8.	0.8	9
223	How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?. Frontiers in Neurology, 2013, 4, 10.	2.4	23
224	Environmental Factors Associated with Disease Progression after the First Demyelinating Event: Results from the Multi-Center SET Study. PLoS ONE, 2013, 8, e53996.	2.5	68
225	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes. Multiple Sclerosis Journal, 2012, 18, 1209-1210.	3.0	2
226	Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis. American Journal of Neuroradiology, 2012, 33, 1573-1578.	2.4	133
227	Interferon-beta or azathioprine as add-on therapies in patients with active multiple sclerosis. Neurological Research, 2012, 34, 923-930.	1.3	7
228	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1819-1828.	13.7	1,041
229	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, The, 2012, 380, 1829-1839.	13.7	1,040
230	Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group. Wiener Medizinische Wochenschrift, 2012, 162, 354-366.	1.1	16
231	Restless legs syndrome in Czech patients with multiple sclerosis: An epidemiological and genetic study. Sleep Medicine, 2012, 13, 848-851.	1.6	38
232	PND58 Effects of BG-12 on Quality of Life in Relapsing–Remitting Multiple Sclerosis: Findings From the Phase 3 Confirm Study. Value in Health, 2012, 15, A556.	0.3	1
233	PND3 Relapses Requiring Intravenous Steroids and Multiple Sclerosis-Related Hospitalizations: Findings From the Phase 3 Define and Confirm Studies. Value in Health, 2012, 15, A546.	0.3	1
234	Cost of multiple sclerosis in the Czech Republic: The COMS study. Multiple Sclerosis Journal, 2012, 18, 662-668.	3.0	34

Eva Kubala Havrdova

#	Article	IF	CITATIONS
235	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal, 2012, 18, 143-152.	3.0	220
236	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. New England Journal of Medicine, 2012, 367, 1087-1097.	27.0	1,161
237	Effect of BC-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study. Multiple Sclerosis Journal, 2012, 18, 314-321.	3.0	63
238	Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. Clinical Neurology and Neurosurgery, 2012, 114, 940-946.	1.4	18
239	Cross Cultural Validation of The Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Clinical Neuropsychologist, 2012, 26, 1186-1200.	2.3	105
240	Corpus Callosum Atrophy – A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study. European Neurology, 2012, 68, 23-27.	1.4	32
241	Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study. PLoS ONE, 2012, 7, e50101.	2.5	73
242	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 2012, 259, 898-905.	3.6	66
243	Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurology, The, 2012, 11, 420-428.	10.2	152
244	Early predictors of non-response to interferon in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 390-397.	2.1	22
245	Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study (S01.003). Neurology, 2012, 78, S01.003-S01.003.	1.1	6
246	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	2.5	35
247	HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. Journal of Neuroimmunology, 2011, 236, 76-80.	2.3	12
248	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758.	10.2	247
249	BC-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. Journal of Neurology, 2011, 258, 449-456.	3.6	45
250	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Annals of Neurology, 2011, 69, 292-302.	5.3	8,001
251	Freedom from disease activity in multiple sclerosis. Neurology, 2010, 74, S3-7.	1.1	125
252	Risks of Immune System Treatments. Science, 2010, 328, 825-826.	12.6	24

#	Article	IF	CITATIONS
253	High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Multiple Sclerosis Journal, 2010, 16, 685-693.	3.0	77
254	Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study. Multiple Sclerosis Journal, 2010, 16, 1360-1366.	3.0	53
255	Patients' Stratification and Correlation of Brain Magnetic Resonance Imaging Parameters with Disability Progression in Multiple Sclerosis. European Neurology, 2009, 61, 278-284.	1.4	10
256	Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 965-976.	3.0	77
257	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurology, The, 2009, 8, 254-260.	10.2	430
258	Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurology, The, 2009, 8, 1111-1119.	10.2	233
259	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. Journal of Neurology, 2009, 256, 405-415.	3.6	193
260	Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis. Journal of the Neurological Sciences, 2009, 282, 112-119.	0.6	84
261	Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations. Journal of Neurology, 2008, 255, 1449-1463.	3.6	204
262	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Annals of Neurology, 2008, 63, 611-620.	5.3	171
263	Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 371, 2085-2092.	13.7	265
264	Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet, The, 2008, 372, 1463-1472.	13.7	457
265	Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 407-414.	1.9	73
266	Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. Physiological Research, 2008, 57, 151-164.	0.9	29
267	Regulation of heme degradation in association with multiple sclerosis. FASEB Journal, 2008, 22, 1013.3.	0.5	0
268	Detection of Cortical Lesions is Dependent on Choice of Slice Thickness in Patients with Multiple Sclerosis. International Review of Neurobiology, 2007, 79, 475-489.	2.0	25
269	The incidence and significance of anti-natalizumab antibodies. Neurology, 2007, 69, 1391-1403.	1.1	312
270	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 2007, 68, 1299-1304.	1.1	123

#	Article	IF	CITATIONS
271	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology, 2007, 68, 1390-1401.	1.1	307
272	Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Current Medical Research and Opinion, 2007, 23, 2823-2832.	1.9	7
273	Healthâ€related quality of life in multiple sclerosis: effects of natalizumab. Annals of Neurology, 2007, 62, 335-346.	5.3	172
274	Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurology, The, 2007, 6, 431-441.	10.2	331
275	Natalizumab in the Treatment of Patients with Multiple Sclerosis: First Experience. Annals of the New York Academy of Sciences, 2007, 1110, 465-473.	3.8	6
276	Neutralising antibodies to interferon \hat{l}^2 in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837.	3.6	48
277	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2006, 354, 899-910.	27.0	2,916
278	A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. European Journal of Neurology, 2006, 13, 61-71.	3.3	46
279	Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Multiple Sclerosis Journal, 2006, 12, 814-823.	3.0	206
280	Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. Multiple Sclerosis Journal, 2006, 12, 108-111.	3.0	4
281	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. Archives of Neurology, 2006, 63, 614.	4.5	81
282	Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 227-234.	3.0	82
283	Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology, 2006, 67, 1717-1718.	1.1	47
284	Aggressive multiple sclerosis—is there a role for stem cell transplantation?. Journal of Neurology, 2005, 252, iii34-iii37.	3.6	10
285	Is it possible to actively and purposely make use of plasticity and adaptability in the neurorehabilitation treatment of multiple sclerosis patients? A pilot project. Clinical Rehabilitation, 2005, 19, 170-181.	2.2	32
286	Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30.	4.5	36
287	Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. Multiple Sclerosis Journal, 2005, 11, 213-221.	3.0	29
288	Immunoablative Therapy with Autologous Stem Cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis Blood, 2005, 106, 5519-5519.	1.4	0

#	Article	IF	CITATIONS
289	Treatment optimization in multiple sclerosis: report of an international consensus meeting. European Journal of Neurology, 2004, 11, 43-47.	3.3	29
290	Markers of bone remodeling predict rate of bone loss in multiple sclerosis patients treated with low dose glucocorticoids. Clinica Chimica Acta, 2004, 348, 147-154.	1.1	22
291	Myelin basic protein in multiple sclerosis and other neurological disorders. Journal of Neurology, 2003, 250, 874-875.	3.6	0
292	Hematopoietic stem cell transplantation for multiple sclerosis. Journal of Neurology, 2002, 249, 1088-1097.	3.6	230
293	Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis. Transplantation Proceedings, 2001, 33, 2179-2181.	0.6	29
294	High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplantation, 2000, 25, 525-531.	2.4	94
295	Atrophy of caudate nucleus in Huntington's disease measured by computed tomography. Journal of Neurology, 2000, 247, 880-881.	3.6	2
296	Occurrence of IgA and IgG Autoantibodies to Calreticulin in Coeliac Disease and Various Autoimmune Diseases. Journal of Autoimmunity, 2000, 15, 441-449.	6.5	52